The Advanced Research Projects Agency for Health (ARPA‑H) awarded grants to seven teams to develop in‑vivo cell therapies that program immune cells inside the body using gene editing, mRNA and other modalities. The awards are part of federal efforts to accelerate therapies that remove the need for ex‑vivo manufacturing and could lower costs and expand access. Projects focus on delivery technologies, selectivity, safety, and scalable manufacturing approaches, and include collaborations across academic labs, startups and established biotech partners. ARPA‑H framed these awards as enabling the next generation of in‑body cell engineering for oncology, autoimmune disease and beyond. The agency’s targeted funding underscores continued government willingness to support high‑risk, high‑return biomedicine and signals a public‑sector driver for companies developing LNP, viral vector and cell‑targeted mRNA platforms.